ArticleACS omega2025
Antiviral Activity of Electrospun Polyamide Ultrathin Fibers Against SARS-CoV-2 Variant.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of new strategies to produce nanomaterials that can be used as personal protective equipment with antiviral activity and low toxicity is crucial. Electrospun ultrathin fibers have attracted considerable attention due to their potential for biomedical applications, including antiviral activity. Herein, we electrospun different grades of commercially available polyamide to produce ultrathin fibers and investigate their antiviral activity against SARS-CoV-2 Gamma lineage (P.1). We evaluated the morphology, chemical composition, and mechanical properties of the ultrathin fibers. We also investigated the in vitro cytotoxicity, hemolytic activity, and antiviral activity against SARS-CoV-2 Gamma lineage (P.1) of the developed ultrathin fibers. The ultrathin fibers had the following diameters and elastic moduli: (i) unmodified crude ultrathin polyamide (PAP) 0.59 μm and 3 MPa, (ii) polyamide Biotech (PAAM) 0.74 μm and 2.2 MPa, and (iii) Amni Virus-Bac OFF polyamide (PAVB) 0.69 μm and 1.06 MPa. The ultrathin PAP fibers showed increased antiviral activity compared to the other ultrathin fibers (PAAM and PAVB). None of the electrospun fibers showed cytotoxicity at the lowest concentration (12.5%). Additionally, hemolysis tests demonstrated a nonhemolytic profile for all fiber groups, reinforcing their biocompatibility and suitability for biomedical applications. The antiviral properties of the electrospun ultrathin PAP fibers, combined with their noncytotoxic and nonhemolytic characteristics, highlight their potential to be used as personal protection against SARS-CoV-2.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.